SWK Holdings (SWKH) Price, Funds Holding, Analyst Price Targets, News & more
SWKH icon

SWK Holdings

17.54 USD
+0.22
1.27%
At close Apr 2, 4:00 PM EDT
1 day
1.27%
5 days
0.23%
1 month
5.54%
3 months
9.62%
6 months
3.12%
Year to date
9.62%
1 year
3.12%
5 years
35.97%
10 years
24.40%
 

About: SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.

Employees: 24

1
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

69% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 13

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

0% more funds holding

Funds holding: 52 [Q3] → 52 (+0) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

4.3% less ownership

Funds ownership: 91.85% [Q3] → 87.56% (-4.3%) [Q4]

14% less capital invested

Capital invested by funds: $196M [Q3] → $170M (-$26.7M) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for SWKH.

Financial journalist opinion

Based on 4 articles about SWKH published over the past 30 days

Neutral
Seeking Alpha
1 week ago
SWK Holdings Corporation (SWKH) Q4 2024 Earnings Call Transcript
SWK Holdings Corporation (NASDAQ:SWKH ) Q4 2024 Earnings Conference Call March 20, 2025 10:00 AM ET Company Participants Susan Xu - IR Jody Staggs - President & CEO Adam Rice - CFO Conference Call Participants Operator Greetings. Welcome to the SWK Holdings Fourth Quarter 2024 Conference Call.
Neutral
Accesswire
2 weeks ago
SWK Holdings Announces Monetization of Royalty Portfolio
DALLAS, TX / ACCESS Newswire / March 19, 2025 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced the monetization of its royalty portfolio through two transactions. On March 17, 2025, ANI Pharmaceuticals, Inc. exercised its buyout option related to the Iluvien royalty, which resulted in a payment of approximately $17.3 million to SWK.
Neutral
Accesswire
2 weeks ago
SWK Holdings Corporation Announces Financial Results for Fourth Quarter 2024
Conference Call Scheduled for Thursday, March 20, 2025, at 09:00 a.m. CST Corporate Highlights Fourth quarter 2024 GAAP net income was $5.9 million, compared with GAAP net income of $2.8 million for the fourth quarter 2023.
Neutral
Accesswire
2 weeks ago
SWK Holdings Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Conference Call
DALLAS, TX / ACCESS Newswire / March 13, 2025 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that it will issue its fourth quarter and full year 2024 earnings results after the market close on Wednesday, March 19, 2025. The Company will host a conference call to discuss its corporate and financial results on Thursday, March 20, 2025 at 10:00am ET.
Neutral
PRNewsWire
1 month ago
ImpediMed Secures $15m Growth Capital Funding
New round will help fuel commercialization efforts in support of ImpediMed's platform technology for the detection and monitoring of lymphedema. CARLSBAD, Calif.
Neutral
Accesswire
2 months ago
SWK Holdings Provides Portfolio Update
DALLAS, TX / ACCESSWIRE / January 6, 2025 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update for material events occurring since September 30, 2024. Originations In November, SWK advanced $5.0M to existing borrower Journey Medical to help fund the company's launch of EmrosiTM.
Neutral
Accesswire
4 months ago
SWK Holdings Corporation Announces Financial Results for Third Quarter 2024
Conference Call Scheduled for Friday, November 15, 2024, at 09:00 a.m. CST Corporate Highlights Third quarter 2024 GAAP net income was $3.5 million, compared with GAAP net income of $4.5 million for the third quarter 2023.
SWK Holdings Corporation Announces Financial Results for Third Quarter 2024
Neutral
Accesswire
5 months ago
SWK Holdings Provides Portfolio Update
Company Announces Q3 Earnings and Conference Call Dates DALLAS, TX / ACCESSWIRE / October 17, 2024 / SWK Holdings Corporation (Nasdaq:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update and announced the anticipated date of the third quarter earnings and conference call schedule. The Company intends to issue their third quarter financials after market close on November 14, 2024, and will host a conference call at 9:00 a.m.
SWK Holdings Provides Portfolio Update
Neutral
Accesswire
7 months ago
SWK Holdings Corporation Announces Financial Results for Second Quarter 2024
Conference Call Scheduled for Friday, August 16, 2024, at 09:00 a.m. CST Corporate Highlights Second quarter 2024 GAAP net income was $4.4 million, compared with net income of $3.9 million for the second quarter 2023 Second quarter 2024 finance receivables segment adjusted non-GAAP net income was $6.5 million, compared with adjusted non-GAAP net income of $7.6 million for the second quarter 2023 As of June 30, 2024, net finance receivables were $265.5 million, a 19.0% increase from June 30, 2023 The second quarter 2024 effective yield was 14.6%, a 10 bps increase from second quarter 2023 As of June 30, 2024, non-GAAP tangible financing book value per share was $20.17, a 6.3% increase from $18.95 at June 30, 2023 DALLAS, TX / ACCESSWIRE / August 15, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided a business update and announced its financial and operating results for the second quarter ended June 30, 2024.
SWK Holdings Corporation Announces Financial Results for Second Quarter 2024
Neutral
Accesswire
8 months ago
SWK Holdings Highlights Recent Achievements and Provides Portfolio Update
DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies. "During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs.
SWK Holdings Highlights Recent Achievements and Provides Portfolio Update
Charts implemented using Lightweight Charts™